Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:30:00 -0400

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website,

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website,

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website,

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website,

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Tue, 12 May 2026 21:49:00 -0400

si-local-file:///var/storage/secattach/20260512/26480042.html

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Tue, 12 May 2026 21:49:00 -0400

si-local-file:///var/storage/secattach/20260512/26480042.html

Aclaris Therapeutis (ACRS) PT Raised to $4 at Stifel

Fri, 08 May 2026 12:28:16 -0400

Stifel analyst Alex Thompson raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $4.00 (from $3.00) while maintaining a Hold rating.

The analyst comments "We remain Hold rated on ACRS following its 1Q26 update. While we are bullish on the potential for both multi-targeting approaches and novel biology within the I&I space featured within the ACRS pipeline, we have challenges with differentiation theses for lead molecules ATI-052 (IL-4RxTSLP) and ATI-2138 (JAK3/ITK). For ATI-052 the selection of IL-4R as a target makes competitive dosing challenging, in our view, vs. other programs targeting exclusively soluble targets. For ATI-2138, we are intrigued by

Aclaris Therapeutis (ACRS) PT Raised to $4 at Stifel

Fri, 08 May 2026 12:28:16 -0400

Stifel analyst Alex Thompson raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $4.00 (from $3.00) while maintaining a Hold rating.

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Fri, 08 May 2026 08:30:00 -0400

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Fri, 08 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Fri, 08 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Fri, 08 May 2026 08:30:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available

Form 10-Q Aclaris Therapeutics, For: Mar 31

Thu, 07 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260507/26454351.html

Form 10-Q Aclaris Therapeutics, For: Mar 31

Thu, 07 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260507/26454351.html

Form 8-K Aclaris Therapeutics, For: May 07

Thu, 07 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260507/26448148.html

Form 8-K Aclaris Therapeutics, For: May 07

Thu, 07 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260507/26448148.html

Aclaris Therapeutics (ACRS) Tops Q1 EPS by 1c

Thu, 07 May 2026 07:03:45 -0400

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $2 million versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Thu, 07 May 2026 06:59:00 -0400

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

- Unique Dual Mechanism of ATI-2138 Supports Planned Phase 2b Clinical Trial in Lichen Planus -